Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zalicus Inc.
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Belgian firm will float on Euronext Brussels; ResMed and Cochlear among existing investors who will invest in at least 25% of shares.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
- Other Names / Subsidiaries
- CombinatoRx, Inc.
- Neuromed Pharmaceuticals Inc.